I-Arcellx, I-CAR T Therapy, INQALI DDBCMA, i-chimeric antigen receptor, IKite Pharma, i-myeloma eminingi
I-KITE NE-ARCELLX VALA ISIVUMELWANO SOKUTHUTHUKISA FUTHI SEBENZE NGOKUHLANGANISA NE-CLINICAL CLINICAL YASEKUGCINENI-DDBCMA KU-MULTIPLE MYELOMA
I-SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, Inkampani yaseGileyadi (NASDAQ: GILD), kanye ne-Arcellx, Inc. (NASDAQ: ACLX), namuhla bamemezele ukuvalwa kwezinkampani ngaphambilini kumenyezelwe amasu omhlaba..
IBHOLA, I-Brexucabtagene autoleucel, IKite Pharma, UTecartus, ZUMA-3
I-Brexucabtagene autoleucel igunyazwe yi-FDA ngokubuyela emuva noma i-refractory B-cell precursor acute lymphoblastic leukemia
Okthoba 2021: I-Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) igunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-B-cell precursor acute lymphoblastic leukemia (YONKE). Nge..
axicabtagene ciloleucel, Ukwelashwa kwe-CAR - T Cell, I-CD19, i-follicular lymphoma, IKite Pharma, i-reflexory follicular lymphoma, kubuyiselwe emuva i-follicular lymphoma, Yescarta
I-FDA inikeze imvume yokusheshisa ye-axicabtagene ciloleucel ye-folloma lymphoma ebuyile noma ephikisayo.
Agasti 2021: I-FDA inikeze i-axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) imvume esheshayo ezigulini ezikhulile ezine-lymphoma ephindaphindekayo noma e-refractory follicular lymphoma (FL) ngemva kwemigqa emibili noma ngaphezulu yokwelashwa kwe-systemic. Ingoma..